



**Supplementary Figure 3: Incremental comparison with the baseline scenario** of (a) the incremental annual number of TB transmission events (drug-sensitive and multidrug-resistant), (b) undiscounted annual incremental quality of life adjusted years (QALYs) gained and (c) undiscounted annual incremental costs (£M), where whole-genome sequencing and/or molecular testing (X or U) are introduced into the conventional TB-diagnosis pathway. Strategies we consider are standard drug sensitivity testing (DST) being replaced by whole-genome sequencing (WGS: red bars), or molecular testing being introduced into the conventional TB-diagnosis pathway with DST (X + DST: blue bars, U + DST: green bars), or molecular testing being introduced into the conventional pathway with WGS in place of DST (X + WGS: purple bars, U + WGS: orange bars). The boxes show the interquartile ranges, and the whiskers the 95% ranges, of the calculated values. TB: tuberculosis.